Sage Total Liab from 2010 to 2024
| SAGE Stock | USD 5.47 0.08 1.44% |
Total Liabilities | First Reported 2012-12-31 | Previous Quarter 69 M | Current Value 70.6 M | Quarterly Volatility 39.1 M |
Check Sage Therapeutic financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sage Therapeutic's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.3 M, Interest Expense of 17.1 M or Selling General Administrative of 144.2 M, as well as many indicators such as Price To Sales Ratio of 14.25, Dividend Yield of 0.0 or PTB Ratio of 1.7. Sage financial statements analysis is a perfect complement when working with Sage Therapeutic Valuation or Volatility modules.
Sage | Total Liab |
Latest Sage Therapeutic's Total Liab Growth Pattern
Below is the plot of the Total Liab of Sage Therapeutic over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Sage Therapeutic's Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sage Therapeutic's overall financial position and show how it may be relating to other accounts over time.
| Total Liab | 10 Years Trend |
|
Total Liab |
| Timeline |
Sage Total Liab Regression Statistics
| Arithmetic Mean | 58,153,422 | |
| Geometric Mean | 42,446,494 | |
| Coefficient Of Variation | 69.96 | |
| Mean Deviation | 34,988,716 | |
| Median | 54,462,000 | |
| Standard Deviation | 40,685,031 | |
| Sample Variance | 1655.3T | |
| Range | 131.7M | |
| R-Value | 0.78 | |
| Mean Square Error | 707.3T | |
| R-Squared | 0.60 | |
| Significance | 0.0007 | |
| Slope | 7,065,751 | |
| Total Sum of Squares | 23173.8T |
Sage Total Liab History
About Sage Therapeutic Financial Statements
Sage Therapeutic stakeholders use historical fundamental indicators, such as Sage Therapeutic's Total Liab, to determine how well the company is positioned to perform in the future. Although Sage Therapeutic investors may analyze each financial statement separately, they are all interrelated. For example, changes in Sage Therapeutic's assets and liabilities are reflected in the revenues and expenses on Sage Therapeutic's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Sage Therapeutic. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Liabilities | 82.7 M | 70.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sage Therapeutic is a strong investment it is important to analyze Sage Therapeutic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sage Therapeutic's future performance. For an informed investment choice regarding Sage Stock, refer to the following important reports:Check out the analysis of Sage Therapeutic Correlation against competitors. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.57) | Revenue Per Share 1.76 | Quarterly Revenue Growth 3.371 | Return On Assets (0.30) | Return On Equity (0.49) |
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.